CSI Laboratories: CSI Laboratories Begins Offering VENTANA PDL1 SP142 Assay as Companion Diagnostic Test for Triple Negative Breast Cancer as a Result of FDA Approval for TENCENTRIQÂ atezolizumab

CSI Laboratories a nationally renowned laboratory specializing in comprehensive cancer diagnostics today announced that it has added the newly approved VENTANA PDL1 SP142 Assay as a companion diagnostic test for use in selecting tri...